Skip to main content
. 2014 Aug 19;5(18):8716–8728. doi: 10.18632/oncotarget.2368

Figure 5. Effect of circulating IL-6 levels on tumor progression and MDSC accumulation in vivo.

Figure 5

a. IL-6 levels in the mice diagnosed with hyperplasia/papilloma or invasive carcinoma were measured using ELISA. Quantitative data are shown. The columns represent the means ± SEM. *, p<0.05. b. Loss of IL-6 decreased the SUVR in the PET images of esophageal lesions in IL-6 KO mice compared with that in the 4-NQO- treated C57 mice with IL-6 stimulation. The tumor-to-muscle SUVR was calculated from the micro-PET scans. Each point represents the means ± SEM. *, p<0.05 c. Flow cytometry analysis of CD11b+Gr1+ cells in the C57 or IL-6 KO mice after treatment with 4-NQO. Representative images and quantitative data are shown. Each column represents the mean ± SD. *, p<0.05 d. Quantitation of the incidence of esophageal tumors with invasive carcinoma using the pathological examination of sectioned tissue samples of the C57 or IL-6 KO mice after treatment. Each column represents the means ± SEM. *, p<0.05.